Directori de persones
Luis Brieva Ruiz

Luis Brieva Ruiz

Grau: Doctor/a

973 705 367
lbrieva.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/E-8505-2019

Grups

Publicacions

  • Fernández-Velasco JI; Monreal E; Kuhle J; Meca-Lallana V; Meca-Lallana J; Izquierdo G; Oreja-Guevara C; Gascón-Giménez F; Sainz de la Maza S; Walo-Delgado PE; Lapuente-Suanzes P; Maceski A; Rodríguez-Martín E; Roldán E; Villarrubia N; Saiz A; Blanco Y; Diaz-Pérez C; Valero-López G; Diaz-Diaz J; Aladro Y; Brieva L; Íñiguez C; González-Suárez I; Rodríguez de Antonio LA; García-Domínguez JM; Sabin J; Llufriu S; Masjuan J; Costa-Frossard L; Villar LM

    Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology.

    Frontiers in Immunology 13 842354-842354. .

    [doi:10.3389/fimmu.2022.842354]

  • de la Maza, SS; Maurino, J; Borges, M; Martín-Martínez, J; Sotoca, J; Alonso, A; Caminero, AB; Borrega, L; Sánchez-Menoyo, JL; Barrero-Hernández, FJ; Calles, C; Brieva, L; Blasco, MR; García-Soto, JD; del Campo-Amigo, M; Navarro-Cantó, L; Agüera, E; Garcés, M; Carmona, O; Gabaldón-Torres, L; Forero, L; Hervás, M; de Alda, LR; Gómez-Ballesteros, R; Castillo-Triviño, T

    Measuring productivity loss in early relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders 58 -. .

    [doi:10.1016/j.msard.2021.103398]

  • Ramo-Tello C; Blanco Y; Brieva L; Casanova B; Martínez-Cáceres E; Ontaneda D; Ramió-Torrentá L; Rovira À

    Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

    Journal of Personalized Medicine 12 -. .

    [doi:10.3390/jpm12010006]

  • Granell-Geli, J; Izquierdo-Gracia, C; Selles-Rius, A; Teniente-Serra, A; Presas-Rodriguez, S; Mansilla, MJ; Brieva, L; Sotoca, J; Mane-Martinez, MA; Moral, E; Bragado, I; Goelz, S; Martinez-Caceres, E; Ramo-Tello, C

    Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab

    Journal of Personalized Medicine 11 -. .

    [doi:10.3390/jpm11121347]

  • Munoz-Lopetegi, A; Pujol, M; Gimenez, M; Gaig, C; Brieva, L; Santamaria, J

    Abnormal sleep behavior caused by hypoglycemia

    SLEEP MEDICINE 85 268-270. .

    [doi:10.1016/j.sleep.2021.07.029]

  • Meca-Lallana, J; Garcia-Merino, JA; Martinez-Yelamos, S; Vidal-Jordana, A; Costa, L; Eichau, S; Rovira À; Brieva, L; Aguera, E; Zarranz, ARA

    Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies.

    Neurodegenerative Disease Management 11 251-261. .

    [doi:10.2217/nmt-2020-0049]

  • Fernandez-Velasco, JI; Kuhle, J; Monreal, E; Meca-Lallana, V; Meca-Lallana, J; Izquierdo, G; Gascon-Gimenez, F; de la Maza, SS; Walo-Delgado, PE; Maceski, A; Rodriguez-Martin, E; Roldan, E; Villarrubia, N; Saiz, A; Blanco, Y; Sanchez, P; Carreon-Guarnizo, E; Aladro, Y; Brieva, L; Iniguez, C; Gonzalez-Suarez, I; de Antonio, LAR; Masjuan, J; Costa-Frossard, L; Villar, LM

    Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

    Neurology-Neuroimmunology & Neuroinflammation 8 -. .

    [doi:10.1212/NXI.0000000000000940]

  • Maurino J; Sotoca J; Sempere ÁP; Brieva L; López de Silanes C; Caminero AB; Terzaghi M; Gracia-Gil J; Saposnik G

    High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions.

    Patient-Patient Centered Outcomes Research 14 241-248. .

    [doi:10.1007/s40271-020-00454-3]

  • Otero-Romero, S; Rodríguez-García, J; Vilella, A; Ara, JR; Brieva, L; Calles, C; Carmona, O; Casanova, V; Costa-Frossard, L; Eichau, S; García-Merino, JA; Garcia-Vidal, C; González-Platas, M; Llaneza, M; Martínez-Ginés, M; Meca-Lallana, JE; Prieto, JM; Rodríguez-Antigüedad, A; Tintoré, M; Blanco, Y; Moral, E

    Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement

    NEUROLOGIA 36 50-60. .

    [doi:10.1016/j.nrl.2020.02.006]

  • Casado V.; Bonaventura I.; Brieva L.; Martínez-Yélamos S.; Martín G.; Presas-Rodriguez S.; Hervas M.; Hernández J.J.; Munteis E.; Escartin A.; Gubieras L.; Mañé-Martínez M.A.; Ramió-Torrentà L.

    Costes directos de los brotes en pacientes con esclerosis múltiple remitente-recurrente

    Neurology Perspectives 1 160-169. .

    [doi:10.1016/j.neurop.2021.05.003]

  • Meca-Lallana, J. E.; Fernandez-Prada, M.; Garcia Vazquez, E.; Moreno Guillen, S.; Otero Romero, S.; Rus Hidalgo, M.; Villar Guimerans, L. M.; Eichau Madueño S; Fernandez Fernandez, O.; Izquierdo Ayuso, G.; Álvarez Cermeño JC; Arnal Garcia, C.; Arroyo Gonzalez, R.; Brieva Ruiz, L.; Calles Hernandez, C.; Garcia Merino, A.; Gonzalez Platas, M.; Hernandez Perez, M. A.; Moral Torres, E.; Olascoaga Urtaza, J.; Oliva-Nacarino, P.; Oreja-Guevara, C.; Ortiz Castillo, R.; Oterino, A.; Prieto Gonzalez, J. M.; Ramio-Torrenta, L.; Rodriguez-Antiguedad, A.; Saiz, A.; Tintore, M.; Montalban Gairin, X.

    Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    NEUROLOGIA 37 615-630. .

    [doi:10.1016/j.nrl.2019.11.003]

  • Meca-Lallana, J; Maurino, J; Hernández-Pérez MÁ; Sempere, AP; Brieva, L; García-Arcelay E; Terzaghi, M; Saposnik, G; Ballesteros, J

    Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing-Remitting Multiple Sclerosis: Quantifying the Patient's Perspective.

    Neurology and Therapy 9 173-179. .

    [doi:10.1007/s40120-020-00176-6]

Projectes

  • EMCOVID-19: Esclerosis Múltiple y COVID-19
  • "Registro de pacientes con esclerosis múltiple (EM) tratados con Natalizumab en España"
  • UTILIDAD DE LA REALIZACION DE SECUENCIAS DE DIFUSION Y LA DETERMINACION DE BIOMARCADORES EN EL PRONOSTICO DE LOS PACIENTES CON UN ATAQUE ISQUEMICO TRANSITORIO